Dendreon (NASDAQ: [[ticker:DNDN]]), the Seattle-based developer of a new treatment to stimulate the immune system against prostate cancer, said today in its quarterly financial report that it ended September with $259.6 million in cash and investments. That means it burned through about $28 million in cash during the last three months, based on its previous quarterly report, in which it said it finished the month of June with $287.5 million in the bank. The company is preparing to manufacture and market sipuleucel-T (Provenge) for men with terminal prostate cancer. Dendreon raised $221 million in May to pursue that goal.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
